4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Novogenia AG (7V0) operates in the Biotechnology industry and is headquartered in Munich, Germany with about 204 employees. Its market capitalization is roughly €71 million. In the fiscal year ended 2025-12-31, 7V0 reported €54M in revenue and €0M in net income.
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | €54M | €25M | €18M | €210M | — |
| Gross Profit | €18M | €12M | €6M | €120M | — |
| Operating Income (EBIT) | (€11M) | €26M | (€4M) | €65M | — |
| Net Income | €0M | €18M | €0M | €45M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (€4M) | (€2M) | (€2M) | (€2M) | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | €119M | €153M | €179M | €224M | — |
| Total Liabilities | €19M | €47M | €85M | €110M | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 7V0 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms